Why the study?
Does clopidogrel non-response increase the risk of device-related thrombus and thromboembolism after WATCHMAN LAA closure in patients with non-valvular AF?
Does clopidogrel non-response increase the risk of device-related thrombus and thromboembolism after WATCHMAN LAA closure in patients with non-valvular AF?
This case highlights the potential risk of device-related thrombus in clopidogrel non-responders after LAA closure, suggesting a possible role for platelet function testing.
Answers are grounded in this paper and cite their sources.
Clopidogrel non-response may raise post-WATCHMAN thromboembolism risk; hypothesis-generating for platelet function testing utility.
Atrial fibrillation (AF) is associated with an increased risk of stroke and thromboembolism (TE). The WATCHMAN TM left atrial appendage (LAA) closure device is indicated to reduce the risk of TE from the LAA in patients with non‐valvular AF. Here, we present a case of a patient with device‐related thrombus who suffered a TE event two months after WATCHMAN TM LAA closure and two weeks after switching from aspirin plus warfarin to aspirin plus clopidogrel therapy. Laboratory investigation identified the patient to be hypercoagulable and to be a non‐responder to clopidogrel therapy. We discuss the potential role of platelet function testing to prevent device‐related thrombi.
No takes yet. Share an insight, caveat, or question.
Venkataraman et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: